Novo Nordisk, gradually exiting the world of autoimmune R&D, has found a home for one of its former projects, handing a development program over to Johnson & Johnson for an undisclosed sum.
Johnson & Johnson is riding high on strong sales for standout meds, but some slowdown could be on the horizon as competition increases for its top-selling drugs. And J&J is not going down without a fight, planning to roll out new versions of old meds to keep its pharma numbers in tip-top shape.
Johnson & Johnson says it's on track to submit more than 10 new drugs for FDA approval over the next four years, and the company believes each of those contenders has the potential to bring in $1 billion in peak revenue.
Astellas and Medivation may have disappointed analysts with their first-quarter Xtandi sales. But recent script numbers suggest the disappointment may be short-lived--and that the prostate cancer pill may be gaining ground on its head-to-head rival, Johnson & Johnson's Zytiga.
Johnson & Johnson, fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' pipeline of antiviral treatments.
Johnson & Johnson's once-a-month antipsychotic med Invega Sustenna is already raking in blockbuster numbers, but the company is eyeing even bigger sales for its franchise with FDA approval for a longer acting formula.
It took three years of legal wrangling by Johnson & Johnson, but for this kind of reprieve, it was time well spent. The company agreed to pay $7.5 million to wrap up a notorious Arkansas state lawsuit over Risperdal--a tiny fraction of the original $1.2 billion trial verdict.
In a virtuous cycle, Johnson & Johnson is kicking in some more funding for continous manufacturing research by Rutgers University, whose engineers are helping J&J's Janssen unit transition some products to the new technology at a plant in Puerto Rico.
Pfizer and Bristol-Myers Squibb's new-age anticoagulant, Eliquis, has been ramping up after a slow start. But Johnson & Johnson, maker of market leader Xarelto, need not worry, thanks to that med's wide base of indications and hefty clinical trials program.
Johnson & Johnson and Bayer are wont to brag about their achievements with Xarelto, one of the new generation of anticoagulant meds. Rightfully so: Though second to that market by many months, the companies grabbed market share from their old standby rival warfarin and their head-to-head competition Pradaxa, too.